CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
Fluorescein Sodiumdrug
Likely dose
Fluorescein Sodium 1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06054178
NCT06054178Phase 2Completed
CompareCT.gov

Intraoperative Nerve Identification With Fluorescein Sodium

Stanford University·interventional·Posted Sep 26, 2023·Updated May 20, 2026

In Brief

A Phase 2 clinical trial evaluating Fluorescein Sodium for Pleomorphic Adenoma of the Parotid and 5 related conditions. Completed, enrolled 8 participants across 1 site.

Detailed Summary

The purpose of this study is to see if there is benefit in using an IV contrast (sodium fluorescein) to identify nerves during head and neck surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPleomorphic Adenoma of the Parotid, Warthin Tumor, Head and Neck Disorder, Head and Neck, Thyroid Disease, Thyroidectomy
CountriesUnited States
CollaboratorsNational Institute on Deafness and Other Communication Disorders (NIDCD)

Timeline

Phase 2CompletedFinished
202420252026
First PostedSep 26, 2023
Enrollment StartNov 7, 2024
Primary CompletionMay 22, 2025
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 2.8 years ago

Interventions

Fluorescein Sodiumdrug

Intravenous administration of 1 mg/kg. If initial dosing is insufficient, additional doses may be administered up to a total of 3 mg/kg